1Y Target$7.14Near-term target
5Y Target$10.64Compound horizon
10Y Target$27.69Long-dated conviction
FCF-$189mTTM · 03/26FFCF is negative (-$189m) — cash-burning phase; acceptable only for pre-profit spec names · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+242.7%TTM YoYARevenue +242.7% — hypergrowth, top decile
D/E0.14totalA-D/E 0.14 — conservative leverage, strong balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/S20.0xDP/S 20.0x — extreme, prices in flawless execution
PEG—proxy—PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Life Sciences Tools & Services · market cap $1.6b. 19% off the 52-week high of $6.51. Revenue growing +243% — in hypergrowth territory.
Moat
Speculative bucket — the moat thesis is forward-looking; without proven margin structure or capital efficiency yet, the durability argument is about IP / network effects / first-mover position that the company hasn't fully monetized.
Risk
Free cash flow is negative (-$189m) — capital raises or debt issuance likely required; dilution / leverage risk. Currently unprofitable (margin -181.8%) — path to GAAP profitability is the core thesis risk. P/S 20.0x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Horizon
1-3 yr $7.14 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $10.64 — requires the platform / technology to reach commercial scale. 10 yr $27.69 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.